BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29856974)

  • 1. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
    Drake JA; Portnoy DC; Tauer K; Weksler B
    Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    Duan H; Liang L; Xie S; Wang C
    BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
    Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
    Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer.
    Ahmad U; Crabtree TD; Patel AP; Morgensztern D; Robinson CG; Krupnick AS; Kreisel D; Jones DR; Patterson GA; Meyers BF; Puri V
    Ann Thorac Surg; 2017 Jul; 104(1):303-307. PubMed ID: 28433225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer.
    Thomas DC; Arnold BN; Rosen JE; Salazar MC; Detterbeck FC; Blasberg JD; Boffa DJ; Kim AW
    World J Surg; 2018 Jan; 42(1):161-171. PubMed ID: 28799084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
    Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
    Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?
    Bott MJ; Patel AP; Verma V; Crabtree TD; Morgensztern D; Robinson CG; Colditz GA; Waqar S; Kreisel D; Krupnick AS; Patterson GA; Broderick S; Meyers BF; Puri V
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1549-1558.e2. PubMed ID: 27207124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.
    Veluswamy RR; Mhango G; Bonomi M; Neugut AI; Hershman DL; Aldridge MD; Wisnivesky JP
    Ann Am Thorac Soc; 2013 Dec; 10(6):622-8. PubMed ID: 24024700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
    Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
    BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.
    Moreno AC; Haque W; Verma V; Fang P; Lin SH
    Ann Surg Oncol; 2018 May; 25(5):1245-1253. PubMed ID: 29484562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in Guideline-Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer.
    Toubat O; Atay SM; Kim AW; Ding L; Farias AJ; Ebner PJ; McFadden PM; David EA
    Ann Thorac Surg; 2020 May; 109(5):1512-1520. PubMed ID: 31982443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
    Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
    JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non-small cell lung cancer invading the chest wall.
    Drake JA; Sullivan JL; Weksler B
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1794-1802. PubMed ID: 29352585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
    Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
    Foster CC; Rusthoven CG; Sher DJ; Feldman L; Pasquinelli M; Spiotto MT; Koshy M
    Lung Cancer; 2019 Apr; 130():162-168. PubMed ID: 30885339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.